Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1997016966) VIRAL INACTIVATION TREATMENT OF RED BLOOD CELLS USING PHTHALOCYANINES AND RED LIGHT
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1997/016966 International Application No.: PCT/US1996/017528
Publication Date: 15.05.1997 International Filing Date: 04.11.1996
Chapter 2 Demand Filed: 15.05.1997
IPC:
A61K 41/00 (2006.01) ,A61L 2/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
41
Medicinal preparations obtained by treating materials with wave energy or particle radiation
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
L
METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
2
Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
Applicants:
NEW YORK BLOOD CENTER, INC. [US/US]; 310 East 67th Street New York, NY 10021, US (AllExceptUS)
BEN-HUR, Ehud [IL/US]; US (UsOnly)
Inventors:
BEN-HUR, Ehud; US
Agent:
GEORGE, Kenneth, P.; Amster, Rothstein & Ebenstein 90 Park Avenue New York, NY 10016, US
Priority Data:
60/007,30606.11.1995US
Title (EN) VIRAL INACTIVATION TREATMENT OF RED BLOOD CELLS USING PHTHALOCYANINES AND RED LIGHT
(FR) TRAITEMENT POUR INACTIVER DES VIRUS EFFECTUE SUR DES GLOBULES ROUGES, EN UTILISANT DES PHTALOCYANINES ET UNE LUMIERE ROUGE
Abstract:
(EN) Disclosed are two processes. The first process involves treating a red blood cell-containing composition to inactivate an extracellular or intracellular virus which may be present in said red blood cell-containing composition by subjecting said red blood cell-containing composition to a virucidally effective amount of a phthalocyanine and red light, wherein the improvement involves: (i) determining the action spectrum of said phthalocyanine for causing inactivation of said virus; (ii) determining the action spectrum of said phthalocyanine for causing red blood cell damage; (iii) comparing (i) and (ii), and, if (i) and (ii) are not identical, then determining the wavelength at which the largest favorable difference exists between (i) and (ii); (iv) providing a red light source emitting red light only in 10 nm in either direction of the wavelength determined in (iii); and then (v) subjecting said red blood cell-containing composition to said virucidally effective amount of said phthalocyanine and said provided red light source. In a preferred embodiment, the phthalocyanine is Pc 4, which has the formula: HOSiPcOSi(CH3)2(CH2)3N(CH3)2. The second process involves transfusing red blood cells to a patient in need thereof by withdrawing red blood cells from a donor, subjecting the red blood cells to the first process and transfusing the red blood cells to said patient.
(FR) L'invention concerne deux procédés. Le premier procédé fait appel à un traitement d'une composition contenant des globules rouges pour inactiver des virus extracellulaires ou intracellulaires qui peuvent être présents dans la composition en question, en la traitant avec des doses de phtalocyanine et de lumière rouge suffisantes pour avoir un effet virocide. L'amélioration de l'invention consiste à: (i) déterminer le spectre d'action de ladite phtalocyanine par rapport à l'inactivation des virus; (ii) déterminer le spectre d'action de la phtalocyanine par rapport aux dommages causés aux globules rouges; (iii) comparer (i) et (ii) et si (i) et (ii) ne sont pas identiques, déterminer la longueur d'onde pour laquelle la différence la plus favorable (c'est-à-dire la plus grande) existe entre (i) et (ii); (iv) fournir une source de lumière rouge émettant uniquement jusqu'à 10 nm dans les deux directions depuis la longueur d'onde déterminée en (iii); et ensuite (v) à soumettre ladite composition contenant des globules rouges à des doses suffisantes de phtalocyanine et de lumière rouge pour produire un effet virocide. Selon une forme d'exécution préférée, la phtalocyanine est la Pc 4, dont la formule est HOSiPcOSi(CH3)2(CH2)3N(CH3)2. Le second procédé fait appel à une transfusion de globules rouges à un patient nécessitant une telle transfusion, consistant à prélever du sang chez un donneur, à soumettre les globules rouges au premier procédé et à les transfuser au patient.
Designated States: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN
African Regional Intellectual Property Organization (ARIPO) (KE, LS, MW, SD, SZ, UG)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP0881874US6090599JP2000500137CA2236873AU1996076672